Akums Drugs and Pharmaceuticals on Friday announced that it has been awarded a patent for its Room Temperature Stable Oral Suspension of Hydroxyurea, a breakthrough formulation aimed at managing Sickle Cell Disease (SCD).
According to the company’s statement, this development reinforces Akums’ role as an innovator in pharmaceutical solutions, offering a significant advance in addressing the storage and accessibility challenges associated with Hydroxyurea solution.
Sickle Cell Disease, a genetic blood disorder, leads to severe health complications such as anemia, frequent pain episodes and other debilitating symptoms, affecting millions worldwide especially in India and Africa. According to the 2011 Census, 8.6% of India’s population is from tribal communities, many of whom are disproportionately affected by SCD. Addressing this pressing public health issue, Akums’ new formulation offers a key advantage over traditional Hydroxyurea solution that require refrigeration between 2–8°C. The new oral suspension remains stable at room temperature, providing a practical solution for widespread distribution, particularly in the tribal areas with limited access to cold storage facilities.
“We are proud to have secured this patent for a formulation that has the potential to improve the lives of countless SCD patients both in India and Africa. At Akums, we are committed to delivering innovative healthcare solutions that address real-world challenges and positively impact patient outcomes. Our constant endeavor is to work on affordable medicines for Orphan Drugs and reduce dependency on imported medicines ensuring patient safety from rare diseases with timely and necessary treatment,” Sanjeev Jain, Managing Director of Akums, said in a statement.
In comparison to Hydroxy Urea Capsule (500mg), Akums Hydroxy Urea suspension offers dose flexibility based on body weight of the SCD Patients, thus offer significant advantage for pediatric and adolescent patients, it claimed.
The patented formulation will now come at fraction of the cost of imported Hydroxyurea solution, this is in line with our commitment to provide affordable quality medicines in India. With this new patent, Akums continues to advance healthcare through innovation, ensuring life-saving treatments reach those who need them the most, it added.
